TNXP Quote, Financials, Valuation and Earnings

Cognition Therapeutics has a net margin of -856.24% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -138.47% beat Cognition Therapeutics's return on equity of --.

Tonix Pharmaceuticals Holding has a consensus price target of $406.67, signalling upside risk potential of 1916.2%. On the other hand Cognition Therapeutics has an analysts' consensus of $5.40 which suggests that it could grow by 1199.01%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Cognition Therapeutics, analysts believe Tonix Pharmaceuticals Holding is more attractive than Cognition Therapeutics.

Tonix Pharmaceuticals Holding has a beta of 2.226, which suggesting that the stock is 122.624% more volatile than S&P 500. In comparison Cognition Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cognition Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Cognition Therapeutics pays out -- of its earnings as a dividend.

Tonix Pharmaceuticals Holding quarterly revenues are $2.6M, which are larger than Cognition Therapeutics quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$22.1M is lower than Cognition Therapeutics's net income of -$7.8M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Cognition Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 2.53x versus -- for Cognition Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Cocrystal Pharma has a net margin of -856.24% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -138.47% beat Cocrystal Pharma's return on equity of --.

Tonix Pharmaceuticals Holding has a consensus price target of $406.67, signalling upside risk potential of 1916.2%. On the other hand Cocrystal Pharma has an analysts' consensus of $8.33 which suggests that it could grow by 463.06%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Cocrystal Pharma, analysts believe Tonix Pharmaceuticals Holding is more attractive than Cocrystal Pharma.

Tonix Pharmaceuticals Holding has a beta of 2.226, which suggesting that the stock is 122.624% more volatile than S&P 500. In comparison Cocrystal Pharma has a beta of 2.347, suggesting its more volatile than the S&P 500 by 134.714%.

Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cocrystal Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Cocrystal Pharma pays out -- of its earnings as a dividend.

Tonix Pharmaceuticals Holding quarterly revenues are $2.6M, which are larger than Cocrystal Pharma quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$22.1M is lower than Cocrystal Pharma's net income of -$4.9M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Cocrystal Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 2.53x versus 7.49x for Cocrystal Pharma. Usually stocks with elevated PS ratios are considered overvalued.

PDS Biotechnology has a net margin of -856.24% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -138.47% beat PDS Biotechnology's return on equity of --.

Tonix Pharmaceuticals Holding has a consensus price target of $406.67, signalling upside risk potential of 1916.2%. On the other hand PDS Biotechnology has an analysts' consensus of $8.13 which suggests that it could grow by 544.84%. Given that Tonix Pharmaceuticals Holding has higher upside potential than PDS Biotechnology, analysts believe Tonix Pharmaceuticals Holding is more attractive than PDS Biotechnology.

Tonix Pharmaceuticals Holding has a beta of 2.226, which suggesting that the stock is 122.624% more volatile than S&P 500. In comparison PDS Biotechnology has a beta of 1.676, suggesting its more volatile than the S&P 500 by 67.622%.

Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PDS Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. PDS Biotechnology pays out -- of its earnings as a dividend.

Tonix Pharmaceuticals Holding quarterly revenues are $2.6M, which are larger than PDS Biotechnology quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$22.1M is lower than PDS Biotechnology's net income of -$10.7M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while PDS Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 2.53x versus -- for PDS Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.

Rafarma Pharmaceuticals has a net margin of -856.24% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -138.47% beat Rafarma Pharmaceuticals's return on equity of --.

Tonix Pharmaceuticals Holding has a consensus price target of $406.67, signalling upside risk potential of 1916.2%. On the other hand Rafarma Pharmaceuticals has an analysts' consensus of -- which suggests that it could fall by --. Given that Tonix Pharmaceuticals Holding has higher upside potential than Rafarma Pharmaceuticals, analysts believe Tonix Pharmaceuticals Holding is more attractive than Rafarma Pharmaceuticals.

Tonix Pharmaceuticals Holding has a beta of 2.226, which suggesting that the stock is 122.624% more volatile than S&P 500. In comparison Rafarma Pharmaceuticals has a beta of 0.976, suggesting its less volatile than the S&P 500 by 2.411%.

Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rafarma Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Rafarma Pharmaceuticals pays out -- of its earnings as a dividend.

Tonix Pharmaceuticals Holding quarterly revenues are $2.6M, which are larger than Rafarma Pharmaceuticals quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$22.1M is higher than Rafarma Pharmaceuticals's net income of --. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Rafarma Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 2.53x versus -- for Rafarma Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.